Grifols Middle East

DUBAI OFFICE

Since 1940, Grifols has been committed to people's health and well-being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use. Grifols distributes plasma-derived therapies in the Middle East and has a strong presence in the diagnostics market. The Dubai office was established in April 2013 to help support our products and healthcare professionals in the region.

Grifols has a long history in manufacturing plasma-derived products that help improve the quality of life for patients with a variety of chronic and potentially life-threatening diseases and conditions. Nowadays, Grifols is a leader plasma collection with a network of 150 plasma donation centers in the U.S. and a leading producer of plasma-derived therapies.

Grifols' portfolio of plasma-derived therapies includes intravenous immunoglobulins, various specific hyperimmune immunoglobulins for the treatment of potentially fatal infections such as rabies, tetanus, hepatitis B and Rh incompatibility, coagulation factor VIII for blood disorders, albumin and alpha-1-antitrypsin, a protease inhibitor indicated as a replacement therapy for alpha-1 antitrypsin deficiency (a genetic disorder that can cause chronic obstructive pulmonary disease [COPD] such as emphysema and chronic bronchitis).

In the diagnostics field, Grifols is a leader in transfusion medicine with a broad portfolio of products designed to ensure the safety and quality of the transfusion chain. These innovative diagnostic systems and products are designed to support safe and compatible transfusions, monitor therapies, analyze blood coagulation (hemostasis), and detect infectious and autoimmune diseases. Grifols also explores the development of molecular testing and other novel technologies with the potential to further improve treatment outcomes and laboratory efficiency. 

GRIFOLS INTERNATIONAL S.A. DUBAI R.O.

Mr. Gordon Smith
Building 49, Office 406
Dubai Healthcare City
PO Box 505194
Dubai, UAE
Tel.: +971 4 430  2244
Fax.: +971 4 421 9977
Email: middleeast@grifols.com

News


Grifols one of 500 best companies in the world to work for, according to Forbes Magazine Grifols is one of only three Spanish companies included in the list of "500 World's Best Employers" compiled by Forbes and Statista
+ info

Grifols and winery Juvé & Camps: denial Regarding the news spread today by some Spanish media, the company informs that Grifols has not become shareholder of the winery Juvé & Camps.
+ info


Grifols and FC Barcelona's Camp Nou Stadium: denial of rumors Grifols would like to make it clear that the rumours circulating regarding a possible sponsorship and stadium naming deal between F.C. Barcelona and the company are entirely unfounded. The company is not considering any sponsorship deal of this kind.
+ info

FDA approves Grifols Prolastin®-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency Prolastin®-C Liquid is the first liquid formulation of an alpha-1 antitrypsin deficiency replacement therapy manufactured in the U.S. The new formulation marks an important milestone in Grifols' ongoing R&D efforts
+ info


Grifols voluntarily discloses transfers of value The company adopted the EFPIA Code of Conduct in 2015
+ info

Araclon Biotech initiates phase II clinical trials of its Alzheimer's vaccine After receiving approval from the Spanish Agency of Medicinal Products and Medical Devices
+ info

Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation's John W. Walsh Research Fund Honoring the memory of John W. Walsh, co-founder of the Alpha-1 Foundation,
+ info

Grifols and Beckman Coulter Enter into an Exclusive Distribution Agreement Multi-year agreement advances companies' objectives to provide diagnostics solutions that support and improve patient care
+ info


Grifols allocates Euros 218 million to dividends, with a compound annual growth rate of 16% over the last 4 years Grifols holds its Ordinary Annual General Shareholders Meeting with more than 80% of its share capital represented
+ info

Grifols Makes Procleix Zika Virus Assay Available for Screening Blood Donations to Countries Accepting CE Mark Grifols strengthens its Procleix portfolio with the CE marking for Procleix Zika Virus Assay
+ info



Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program Helping treat tens-of-thousands of patients in developing countries; renewing partnership with WFH; reaffirming commitment to improving the lives of patients around the world
+ info

The President of the Company, Víctor Grífols Roura, Honored with the Distinction Creu de Sant Jordi The Creu de Sant Jordi, one of the highest honors awarded by the Government of Catalonia
+ info

Grifols participates at the 3rd International Conference on Research into Alpha-1 Antitrypsin Deficiency, and the 6th International Congress of Alpha-1 Patients Patients and researchers from across the world are meeting to discuss the latest scientific advances in alpha-1 antitrypsin deficiency, a rare genetic disease that can cause respiratory illness, particularly emphysema
+ info


Grifols refinances debt for USD 6.3 billion, reducing the margin to 200 bps and extending its maturities The company has concluded its debt refinancing process substantially improving all conditions
+ info

Grifols closes the acquisition of Hologic's share of NAT donor screening unit for USD 1,850 million The company consolidates a leading position of its Diagnostic Division enhancing its integration
+ info

Grifols agrees to acquire Hologic's share of NAT donor screening unit for USD 1,850 million The company consolidates a leading position of its Diagnostic Division enhancing its integration
+ info


Grifols relocates its headquarters in Germany to a new office building Grifols has a commercial subsidiary in Germany since 1997 and following the acquisition of Talecris in 2011, the country also hosts the commercial headquarters of the Bioscience Division in Europe
+ info

Grifols Opens Diagnostic Training Center in Dubai The new center, part of Grifols growing Diagnostic business, will train laboratory technicians, engineers, and specialists on Grifols systems and laboratory best practices
+ info

Grif_ls supports the Canadian Blood Services' Missing Type Campaign Grif_ls is proud to support the Canadian Blood Services' Missing Type Campaign. This is a global campaign whose goal is to increase the number of new registered blood donors. In the last decade there has been a downward trend of new registered blood donors, which may put the blood supply at risk
+ info

The results of phase I clinical trial of the Araclon Biotech Alzheimer's vaccine support its continuation The conclusions of the trial were presented at the Alzheimer's Association International Conference in Toronto. The compound ABvac40, designed to combat Alzheimer's disease at its initial stage, has demonstrated a good safety and tolerability profile.
+ info


Award Winners of the 9th Annual Martín Villar Haemostasis Awards The awards ceremony was held at the symposium organized by Grifols at the WFH World Congress in Orlando on July 26, 2016
+ info

Grifols agrees to acquire a 517,000 sq ft plot of land to expand its production facilities in Barcelona, Spain The plot is located in the Spanish town of Lliçà de Vall, a future industrial park adjacent to the industrial park of Llevant of Parets del Vallès, where currently Grifols has production facilities
+ info

Pedigri®: the tool that increases the information transparency to the plasma-derived manufactured in Clayton GammaSTAN®, Gamunex® / Gamunex-C®, HyperHEP B®, HyperRAB®, HyperRHO®, HyperTET®, Koāte® DVI, Plasbumin®, Prolastin® / Prolastin® C and Thrombate® III are the newly added products
+ info

Award Winner of the 2016 SPIN Awards Program Created in 2008, the SPIN Awards Program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology.
+ info

FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol Blood banks will use the new test, co-developed by Hologic and Grifols, to screen donated blood in potential endemic areas of the US.
+ info


SIPPET, an international randomized study, reports 87% higher incidence of inhibitors with recombinant factor VIII in patients with severe hemophilia A Results of the study have just been published in the May 26th issue of the New England Journal of Medicine
+ info

Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the Bioscience Division The company has announced a new industrial expansion plan and continues with its initiatives to increase access to plasma
+ info

The Catalan Down's Syndrome Foundation and Grifols are working together to promote research Grifols has donated 150,000 euros to support the Foundation's research effort, designed to improve the quality of life of people with intellectual disability
+ info

Lurie Children's Hospital Selects Grifols KIRO® Robot to Increase Precision, Safety, and Compliance of Pediatric IV Chemotherapy Handling and Compounding Grifols KIRO robotic system provides next-generation precision and automation for sterile compounding of IV medications.
+ info

The company doesn´t have any tax litigation in any country where it operates Because of the dissemination of some information with regard the Grifols S.A. 2015 consolidated annual accounts, filed with the CNMV last Monday, the company would like to clarify the following points
+ info

Grifols' revenues grow by 17.3% to Euros 3,935 million, and net profit grows by 13.2% reaching Euros 532 million Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) reported net revenues of Euros 3,934.6 million for 2015, growing +17.3% compared to Euros 3,355.4 million reported in 2014. Exchange rates movements, in particular of the US Dollar, had a positive impact on revenues; that grew +2.5% at constant currency (cc).
+ info

Grifols invests in the project led by AlbaJuna Therapeutics, a spin-off from IrsiCaixa, to fund the development of therapeutic antibodies against HIV AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the "natural killer" cells responsible for destroying cells infected by the virus
+ info

Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine in U.S. Almost all cases of tetanus in the U.S. occur in people who have never been immunized or who have not had a tetanus booster shot within the preceding 10 years
+ info

Grifols makes public its succession plan: the envisaged generational handover reiterates the commitment of the founding family to the company From 1 January 2017 Victor Grifols Roura will be succeeded by his brother, Raimon Grifols, and his son, Víctor Grifols Deu, who will become joint and several chief executive officers of the company. Víctor Grifols will continue holding his position as non-executive chairman of the board of directors
+ info

The SIPPET Study on inhibitors in Hemophilia A reports a higher incidence of inhibitors with recombinant factor VIII than plasma-derived factor VIII containing von Willebrand factor The results may have implications in the choice of products for management in previously untreated patients (PUPs) with severe hemophilia A
+ info

Inauguration of the Grifols Chair for the Study of Cirrhosis The Grifols Chair for the Study of Cirrhosis, a private chair with an international reach, was created to promote research and education on liver diseases, especially cirrhosis
+ info

The intermediate results from the Grifols AMBAR study support its continuation The intermediate results show the tolerability and safety of the treatment
+ info

Grifols agrees long term loan with the European Investment Bank Grifols is one of the first companies to receive funding from the European Investment Bank (EIB) through the new European Fund for Strategic Investments (EFSI)
+ info

Grifols official opening of the Bioscience Division new worldwide operations facility in Ireland Total investment in the project reaches 100 million dollars and is a fundamental part of Grifols' growth strategy
+ info

Grifols Announces the 2015 ALTA Award Winners during the ERS Congress in Amsterdam The annual ALTA award, sponsored exclusively by Grifols, provides two fellowships of €50,000 to young investigators and clinicians whose work contributes to the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency).
+ info

Grifols Antithrombin Research Awards (GATRA) Program 2015 On October 13th, the ceremony for the first edition of the GATRA Program (Grifols Scientific Awards about research on antithrombin) was held at the Museu Grifols in Barcelona.
+ info

Albumin Awards Program (Albus) 2015 Berlin held the ceremony of the first edition of the Albus Awards
+ info